Drugs / BSA204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07551505 | Apr 2026 → Jul 2027 expected | hyperlipidemia | Bisirna Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSA204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551505 ↗ |